Welcome to our dedicated page for PARABILIS MEDICINES SEC filings (Ticker: PBLS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on PARABILIS MEDICINES's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into PARABILIS MEDICINES's regulatory disclosures and financial reporting.
Parabilis Medicines, Inc. is a clinical-stage biopharmaceutical company planning an initial public offering of voting common stock on the Nasdaq Global Market under the symbol PBLS, alongside a concurrent $75.0 million private placement to Regeneron at 90% of the IPO price.
The company is developing Helicons, stabilized helical peptides designed to drug historically undruggable intracellular targets. Lead candidate zolucatetide targets the Wnt/β‑catenin pathway and has treated over 150 patients. In desmoid tumors, all 25 response‑evaluable patients showed tumor reductions and 74% of 19 patients with at least two post‑baseline scans achieved an objective response.
Parabilis is also studying zolucatetide in familial adenomatous polyposis, hepatocellular carcinoma, additional rare Wnt/β‑catenin–driven tumors, and colorectal cancer, and advancing ERG and ARON degraders for prostate cancer. The company reported a net loss of $145.9 million in 2025 and had cash and cash equivalents of $329.0 million and an accumulated deficit of $586.8 million as of March 31, 2026. Proceeds from the IPO and private placement, plus a $50.0 million upfront Regeneron payment, are earmarked mainly for zolucatetide clinical programs, pipeline advancement, platform development, and general corporate purposes.